Could a common heart drug boost cancer treatment?
NCT ID NCT05651594
First seen Jan 04, 2026 · Last updated Jun 12, 2026 · Updated 28 times
Summary
This study tests whether adding propranolol (a beta-blocker used for heart conditions) to standard chemotherapy and immunotherapy can help shrink tumors in people with advanced esophageal or gastroesophageal junction cancer that cannot be surgically removed. The trial enrolls 40 adults who have not received prior treatment for their advanced cancer. Researchers believe propranolol may reduce stress-related hormones that can weaken the immune system, potentially making the other treatments more effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE II ESOPHAGEAL ADENOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.